Cleveland BioLabs is a drug discovery and development company leveraging its proprietary mechanistic discoveries about programmed cell death to treat cancer and protect normal tissues from exposure to radiation and other stresses. CBLI has strategic partnerships with the Cleveland Clinic, Roswell Park Cancer Institute, ChemBridge Corporation and the Armed Forces Radiobiology Research Institute.

The Company's proprietary technology platform is based on the ability to suppress or stimulate programmed cell death (apoptosis). CBLI's drugs can switch apoptosis on and off by affecting key regulators of cell response to stresses, such as radiation or ischemia.

CBLI is pursuing 3 key areas of research: Biodefense for Acute Radiation Syndrome (ARS), Cancer Treatment, and Tissue Protection. The Company has a strong intellectual property position covering its drug discovery technology and products, including 16 pending patents.

CBLI’s pipeline includes products from two primary families of compounds: Protectans and Curaxins. Protectans are being developed as drug candidates that protect normal tissues from acute stresses such as radiation, chemotherapy and ischemias (pathologies developed as a result of blocking blood flow to a part of the body). Curaxins are being developed as anticancer agents that could act as mono-therapy drugs or in combination with other existing anticancer therapies.

The Company has a strong intellectual property position covering its drug discovery technology and products, including granted patents for CBLLB502.